Randomized phase I trial of antigen-specific tolerizing immunotherapy with peptide/calcitriol liposomes in ACPA+ rheumatoid arthritis

Abstract

surrounding technology for targeting DCs for antigen-specific tolerance and funding from Janssen Biotech Inc. to Uniquest resulting in development and trial of DEN-181. IG, MR, SB, and KC were employees of Janssen when the study took place.